The Keytruda Market is characterized by a diverse range of cancer types and therapeutic approaches, each shaping the market's growth trajectory. Valued at USD 30.62 billion in 2025 and projected to reach USD 41.72 billion by 2035, the market's expansion is closely tied to the dynamics of its core segments. The cancer type landscape is led by Non-Small Cell Lung Cancer (NSCLC) , while the therapy landscape is dominated by Monotherapy [source: Market Research Future].

Cancer Type Dynamics: NSCLC Leads, Emerging Indications Grow

In terms of cancer type, Non-Small Cell Lung Cancer (NSCLC) holds the largest market share (approximately 42%). This dominance is driven by the sheer volume of eligible patients across first-line, adjuvant, and maintenance settings. The KEYNOTE-024, KEYNOTE-189, and KEYNOTE-042 trials established pembrolizumab as the preferred first-line treatment for PD-L1-positive NSCLC, with subsequent adjuvant approvals expanding the patient population. While NSCLC leads, the "Others" category (including endometrial, cervical, biliary tract, and tumor-agnostic MSI-H/dMMR approvals) is the fastest-growing segment. The steady accumulation of new indications through label expansions is creating a diversified and expanding revenue stream. Melanoma sustains a steady CAGR, while Head and Neck Squamous Cell Carcinoma (HNSCC) also represents a significant segment. The comprehensive Keytruda Market report highlights these important cancer type trends.

Therapy Type Dynamics: Monotherapy Dominates, Combination Therapy Emerges

Monotherapy holds the largest share (approximately 38%) of the Keytruda Market. This is supported by broad single-agent label approvals across multiple tumor types, particularly in high PD-L1-expressing tumors (TPS ≥50%) and MSI-H solid tumors. While monotherapy leads, Combination Therapy is the fastest-growing segment (CAGR of 3.9%). The shift toward pairing pembrolizumab with platinum-doublet chemotherapy in NSCLC and with lenvatinib in endometrial cancer has generated clinically meaningful improvements in progression-free survival. Combination protocols now represent the majority of new pembrolizumab prescriptions in first-line settings for several major indications.

Impact on Distribution and Future Trends

These dynamics influence the distribution landscape. The dominance of infusion-based monotherapy and combination regimens supports the leading role of Hospital Pharmacies as the primary channel. However, the anticipated development of a subcutaneous formulation could shift a meaningful volume toward Specialty Pharmacies, particularly for maintenance dosing in stable patients. The future of the Keytruda Market will be defined by the continued expansion of indications, the maturation of combination strategies, and the development of more convenient administration routes.